

Drug Utilization Review (DUR) Meeting Minutes
June 2, 2014

Members Present: Norman Byers, John Savageau, Jeffrey Hostetter, Peter Woodrow, Carrie Sorenson, Russ Sobotta, Tanya Schmidt, Steve Irsfeld, Michael Booth, Cheryl Huber, Gary Betting, Leann Ness

Members Absent: Todd Twogood, Carlotta McCleary, James Carlson

Medicaid Pharmacy Department: Brendan Joyce

J. Savageau called the meeting to order at 1:00 p.m. Chair J. Savageau asked for a motion to approve the minutes from the March meeting. T. Schmidt moved that the minutes be approved, and N. Byers seconded the motion. Chair J. Savageau called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Cathflo Second Review

A motion and second were made at the March meeting to place Cathflo on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent. The form will be labeled Alteplase.

Intranasal Cyanocobalamin Products Second Review

A motion and second were made at the March meeting to place intranasal cyanocobalamin products on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Luzu Second Review

A motion and second were made at the March meeting to place Luzu on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Noxafil Second Review

A motion and second were made at the March meeting to place Noxafil on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Bethkis Second Review

A motion and second were made at the March meeting to place Bethkis on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Name Brand Narcotics

B. Joyce discussed with the board changing the name of the form to Narcotics PA form. All narcotics will require a prior authorization except generic MS Contin. In the future, PDMP reports may be required from prescribers when requesting a narcotic.

Medicaid Expansion Drug Coverage

Michael Crandell, Chief Medical Officer of Sanford Health Plan, spoke with the committee about Medicaid expansion in North Dakota.

Cayston Review

B. Joyce reviewed Cayston information with the board. There was no public comment. P. Woodrow made a motion to place Cayston on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Procysbi Review

B. Joyce reviewed Procysbi information with the board. There was no public comment. The committee agreed that Procysbi should be included in the >\$3,000 prior authorization.

Ravicti Review

B. Joyce reviewed Ravicti information with the board. There was no public comment. Ravicti is also >\$3,000. The board agreed that the state should PA all high cost medications \$3,000 and over and report back to the board on drugs that were added.

Gastrointestinal Agents Review

B. Joyce reviewed gastrointestinal agents with the board. There was no public comment. This topic was tabled.

Myalept Review

B. Joyce reviewed Myalept information with the board. There was no public comment. This topic was tabled.

Northera Review

B. Joyce reviewed Northera information with the board. There was no public comment. M. Booth made a motion to place Northera on prior authorization. C. Sorenson seconded the motion. This topic will be reviewed at the next meeting.

Oral Allergen Extracts Review

B. Joyce reviewed oral allergen extracts with the board. There was no public comment. M. Booth made a motion to place oral allergen extracts on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Hostetter asked that criterion #36 dealing with high doses of statins and diabetes be brought back to the next meeting. J. Hostetter moved to approve the new criteria (without #36) and P. Woodrow seconded the motion. Chair J. Savageau called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held September 3, in Bismarck. N. Byers made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. J. Savageau adjourned the meeting.